Track market-moving stories before they get noisy

If you're seeking solid dividend-paying stocks for your portfolio, don't just look for the fattest dividend yields. For one thing, many high-yielding stocks are high-yielding simply because their stock prices have fallen hard -- very possibly for good reason. Also, it's important to focus not just on a dividend's size, but also its growth rate.

Imagine, for example, that you're thinking of investing in Company A or Company B. The yield for A is 3% and for B, 2%. It might seem smarter to invest in A, but if B's dividend payout is growing at a good clip, its yield could surpass that of A within a few years. Of course, you'll also want to evaluate much more than just dividend yields.

Image source: Getty Images.

Consider Becton, Dickinson Here's a very promising dividend payer to consider: Becton, Dickinson (BDX 1.61%), also known as "BD." It's a medical products company, collecting much of its revenue from products such as syringes, blood collection tubes, catheters, infusion systems, and so on. Such items are always needed, so they provide a lot of recurring revenue. Indeed, 90% of the company's revenue is from such consumables.

Today's Change

(

-1.61

%) $

-2.54

Current Price

$

155.63

Becton, Dickinson recently yielded 2.7%, which is pretty good. (The S&P 500's overall dividend yield has been roughly 1.1% for a long time now.) Better still, that payout is growing briskly: It averaged annual growth of 10.5% over the past five years. On top of that, the company has been hiking its payout annually for 54 years -- so far.

Becton, Dickinson's stock is attractively priced at recent levels, too, with a recent forward-looking price-to-earnings (P/E) ratio of 12, well below its five-year average of 16. And its price-to-sales ratio was recently 2.2, below its five-year average of 3.2.

Here's another bonus for shareholders: The company has been buying back (and retiring) lots of its stock -- leaving remaining shares worth more. If you combine the dividend yield and the effect of share buybacks, the company's recent total yield is 8.3%.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Becton Dickinson (BDX - Free Report) , which belongs to the Zacks Medical - Dental Supplies industry.

This medical device manufacturer has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3.94%.

For the most recent quarter, Becton Dickinson was expected to post earnings of $2.77 per share, but it reported $2.9 per share instead, representing a surprise of 4.69%. For the previous quarter, the consensus estimate was $2.82 per share, while it actually produced $2.91 per share, a surprise of 3.19%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Becton Dickinson lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Becton Dickinson currently has an Earnings ESP of +2.66%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Many investors are chasing life-changing gains by buying shares in top artificial intelligence companies. That makes sense. The industry could offer (and already has offered) multiple transformative investment opportunities. It's a great idea to try to capitalize on this. However, it's also important not to forget about other proven strategies for earning solid long-term returns, one of which is to invest in strong dividend-paying corporations. With that in mind, let's consider three dividend stocks that are worth buying right now: AbbVie (ABBV +2.06%), Walmart (WMT +2.11%), and Becton, Dickinson (BDX +2.28%).

Image source: Getty Images.

1. AbbVie AbbVie, a leading pharmaceutical company, has not performed well this year. The company's shares are down 5% year to date. However, that has as much to do with broader weakness in the healthcare sector as anything AbbVie did wrong. In fact, the company's financial results have been pretty strong. The drugmaker exceeded expectations in the first quarter. Further, AbbVie's long-term outlook remains bright. The company's two main growth pillars, Skyrizi and Rinvoq, continue to defy expectations and should remain important growth drivers into the next decade.

Today's Change

(

2.06

%) $

4.75

Current Price

$

234.76

AbbVie has several other important products, including its Botox franchise, among others. The company also has a deep pipeline, with several exciting products that could eventually become meaningful growth drivers, including in the weight loss market. AbbVie has overcome significant patent cliffs in the past and should do so again, thanks to its innovative qualities. Finally, AbbVie is a fantastic dividend stock. It is a member of the Dividend Kings, a group of companies that have achieved at least 50 consecutive years of payout increases. All these factors make AbbVie a solid dividend stock to buy and hold onto for a while.

2. Walmart Walmart's shares dropped significantly after its latest earnings. Though its results were pretty good, the company's outlook did not inspire confidence. There is no question that Walmart may have a rough go of it in the near term. Broader economic problems, such as inflation and tariffs, may lead to lower foot traffic in its stores and overall unimpressive sales. However, it remains an excellent stock to buy and hold. Here are three reasons why. First, even in the current environment that will be unfriendly to much of the retail industry, Walmart should perform better than most of its peers thanks to its ability to offer competitive prices. Walmart is known for its Everyday Low Price guarantee, and combined with its significant retail footprint, it should help the company generate somewhat decent sales and earnings even if we enter a recession.

Today's Change

(

2.11

%) $

2.47

Current Price

$

119.65

Second, Walmart is tapping into important long-term opportunities that should help improve its profits and margins. The company's higher-margin e-commerce operations have been growing faster than the rest of the business for years and are also helping it ramp up its digital advertising unit, another highly profitable business. Both e-commerce and digital advertising have a long runway for growth, and that's great news for Walmart. Finally, the company also has an impressive dividend track record. It has recorded 53 consecutive years of dividend increases, making it a Dividend King. Walmart is a great income play for investors focused on the long haul.

3. Becton, Dickinson Becton, Dickinson has been facing challenges for years. Between broader economic problems and slow revenue and earnings growth, the company's shares have lagged the market. However, the stock could still deliver competitive returns -- especially with dividends reinvested -- for investors willing to be patient. Despite the headwinds it has faced, the medical device specialist remains a leader in its niche, providing a range of devices and tools healthcare professionals use regularly. The list includes items such as needles and syringes, specimen collection tools, infusion systems, and more.

Crucially, over 90% of the company's revenue is from recurring consumables. Also, the company has spun off several parts of the business -- including most recently its biosciences and diagnostic solutions segment. Getting rid of this lower growth unit should help boost the company's sales growth.

Today's Change

(

2.28

%) $

3.21

Current Price

$

143.92

Further, Becton, Dickinson has several attractive opportunities, one of the most important being in the GLP-1 market. The company provides pharmaceutical leaders with prefillable syringes that patients use to inject themselves with GLP-1 medications. Becton, Dickinson set a goal of reaching $1 billion in GLP-1-related revenue by the end of the decade, and the company said earlier this year that it was almost halfway there. Beyond that, Becton, Dickinson's innovative qualities should help it pounce on other growth avenues. Finally, the company is also a Dividend King, having raised its payouts for 54 consecutive years. It'd be a great move for dividend seekers to buy this company's shares on the dip.

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.

By integrating the BD Pyxis™ Pro and BD Alaris™ platforms, Wellstar Health System is giving clinicians clearer insight, greater accuracy and simple automation, so they can focus on delivering safer, more consistent care to every patient

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Wellstar Health System, one of Georgia's largest and most integrated healthcare systems, to enhance the safety and quality of medication delivery for patients across its hospitals and care facilities.

BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI Through this collaboration, Wellstar is building a more connected approach to medication management from the pharmacy to the bedside by combining BD Pyxis™ Pro medication dispensing technologies with BD Alaris™ Infusion Systems. By adopting the latest in dispensing and infusion technology, Wellstar is empowering clinicians with greater accuracy, real‑time visibility, and streamlined workflows, helping them focus more on delivering safe, dependable care to their patients.

Powered by artificial intelligence, the new BD Pyxis™ Pro Dispensing Solution with Analytics in BD Incada™ provides Wellstar with enterprise‑wide visibility into medication inventory, including on‑demand insights through natural‑language queries. Customizable dashboards convert data into actionable intelligence, helping clinicians identify trends to ensure medication availability, reduce medication waste and optimize labor efficiency. And with BD Alaris™ EMR Interoperability, Wellstar clinicians can use barcode scanning to send infusion orders directly from the electronic medical record and receive infusion statuses back into the EMR.

"At Wellstar, our focus is on delivering safe, innovative care to every patient, every time," said Susan Wright, Pharm.D., Vice President, Pharmacy Services at Wellstar Health. "Partnering with BD to implement this technology strengthens our ability to focus on patient-centered programs and empower our teams to deliver care with confidence and compassion."

Wellstar also participates on the Strategic Development Council for BD's Medication Management Solutions business, where Wellstar leaders contribute expertise across enterprise pharmacy operations, medication safety, nursing, and informatics. This input helps inform and shape future innovation at BD and drives next-generation solutions to meet the real‑world challenges faced by large, complex healthcare systems.

"BD is proud to partner with Wellstar to advance medication safety and help ensure patients receive the right medications at the right time," said Connor Bates, Worldwide President for Medication Management Solutions at BD. "By integrating BD Pyxis™ and BD Alaris™ technologies, Wellstar is setting an example of how health systems can achieve connected, intelligent medication management that benefits both patients and clinicians."

This collaboration reflects a shared vision to strengthen safety, efficiency, and patient outcomes across the continuum of care, while positioning Wellstar as a leader in leveraging technology to improve the health of the communities it serves.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

About Wellstar Health System
Wellstar personalizes the patient experience. We call it PeopleCare and it's only possible thanks to our 34,000 team members who provide expert compassionate care for every stage of life. PeopleCare also means we serve our communities as a non-profit health system, providing more than $1 billion annually in charity care and community programs, and operating the largest integrated trauma network in the State of Georgia. We embrace innovation and technology, nurture early-stage companies through our venture firm Catalyst by Wellstar, and train future generations of caregivers with academic institutions including the Medical College of Georgia. Wellstar honors every voice and is one of the Fortune 100 Best Companies to Work For. To learn more, visit Wellstar.org.

Contacts: 

BD Media:

Investors:

Matt Marcus

Shawn Bevec

VP, Public Relations

SVP, Investor Relations

[email protected]

[email protected]

SOURCE BD (Becton, Dickinson and Company)

Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1 , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

"We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Execution was broad-based, with more than 90% of the business delivering mid‑single‑digit growth, strong performance from our growth platforms and ongoing margin momentum from BD Excellence. Based on our first‑half performance and improved visibility into the balance of the year, we are raising our full‑year adjusted EPS guidance and reaffirming our revenue growth expectations. We remain focused on disciplined execution of our New BD strategy, including advancing our commercial and innovation initiatives across key growth platforms, expanding margins, and delivering on our capital allocation framework, all to drive sustainable long‑term shareholder value."

1BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure. See the discussion below under "Full Year Fiscal 2026 Guidance."

Recent Business Highlights

Medical Essentials: Announced the commercial launch of the BD® CentroVena One™ Insertion System, the first all-in-one central venous catheter (CVC) insertion device on the market designed to simplify central line placement and enhance patient safety in acute settings. Connected Care: Announced a strategic partnership with Wellstar Health System to advance patient care and safety with medication management powered by AI, building a more connected approach from the pharmacy to the bedside by integrating the BD® Pyxis™ Pro and BD® Alaris™ Platforms to give clinicians clearer insight, greater accuracy and simple automation. Launched the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe, leveraging advanced automation and AI‑driven insights to improve medication management efficiency and safety across pharmacy settings. Launched the HemoSphere Stream™ Module, expanding access to continuous, noninvasive blood pressure monitoring with real‑time arterial waveform data across compatible bedside monitors and care settings. Announced a partnership with Sinteco to expand advanced robotics for end‑to‑end connected medication management, streamlining pharmacy operations and supporting higher‑quality care. Earned three 2026 Best in KLAS Awards with BD Pyxis™ MedStation™ ES recognized for Automated Dispensing Cabinets and the BD Alaris™ Infusion System for Traditional and EHR-Integrated Smart Pumps. Interventional: Received CE Marking for the Revello™ Vascular Covered Stent, advancing BD's peripheral vascular portfolio with a next-generation endovascular solution for iliac artery treatment. Received CE Marking for the Liverty™ TIPS Stent Graft, advancing portal hypertension care with a next‑generation interventional solution for patients with advanced liver disease. Received FDA 510(k) clearance for Surgiphor™ 1000mL, the first and only 1000 mL antimicrobial wound irrigation system designed for powered lavage, enabling standardized, OR‑ready irrigation. BD named a Top 100 Global Innovator by LexisNexis, reflecting the strength of BD's innovation engine and contributions to sustainable growth, margin expansion and competitive advantage. Basis of Presentation— Continuing Operations

On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.

Second Quarter Fiscal 2026 Operating Results

Three Months Ended March 31,

Reported
Change

Foreign Currency 
Neutral Change1 

(Millions of dollars, except per share amounts)

2026

2025

Revenues

$               4,714

$               4,480

5.2 %

2.6 %

Reported Diluted Earnings per Share

$                (0.13)

$                 0.55

(123.6) %

(130.9) %

Adjusted Diluted Earnings per Share1

$                 2.90

$                 2.79

3.9 %

1.1 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.

Geographic Results

Revenues (Millions of dollars)

Three Months Ended March 31,

Reported
Change

Foreign Currency 
Neutral Change1

2026

2025

United States

$               2,917

$               2,776

5.1 %

5.1 %

International

$               1,797

$               1,704

5.5 %

(1.4) %

Total Revenues

$               4,714

$               4,480

5.2 %

2.6 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.

Segment Results

Revenues (Millions of dollars)

Three Months Ended March 31,

Reported
Change

Foreign Currency
Neutral Change1

2026

2025

Medical Essentials2

$               1,647

$               1,573

4.7 %

1.7 %

Connected Care2

$               1,120

$               1,068

4.9 %

3.2 %

BioPharma Systems2

$                  590

$                  575

2.5 %

(1.8) %

Interventional2

$               1,357

$               1,264

7.3 %

5.3 %

Total Revenues

$               4,714

$               4,480

5.2 %

2.6 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables. 

2Effective October 1, 2025, the company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the company's product and service offerings. Subsequent to the spin-off of the company's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

Full Year Fiscal 2026 Guidance

The company updates its full year fiscal 2026 guidance as follows:

Updated New BD Guidance

as of May 7, 2026

Prior New BD Guidance

as of February 9, 2026

GAAP Revenue Growth

Low single-digit plus

Low single-digit plus

Revenue Growth (FXN)

Low single-digit

Low single-digit

Adjusted Diluted EPS

$12.52 to $12.72

$12.35 to $12.65

BD's guidance for full year fiscal 2026 reflects numerous assumptions that could affect its business, based on the information management has reviewed as of this date. Management will discuss its guidance and several of its assumptions on its second fiscal quarter earnings call.

The company's expected adjusted diluted EPS for fiscal 2026 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our revenue growth for our 2026 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying revenue performance for our 2026 fiscal year in relation to our underlying 2025 fiscal year performance.

Conference Call and Presentation Materials
BD will host an audio webcast today for the public, investors, analysts and news media to discuss its second quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors, at 8 a.m. (ET) Thursday, May 7, 2026. Accompanying slides will be available on BD's website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-688-9445 (domestic) and 402-220-1371 (international) through the close of business on Thursday, May 14, 2026. A confirmation number is not needed to access the replay.

Non-GAAP Financial Measures/Financial Tables
This press release contains certain non-GAAP financial measures. These include revenue growth rates on a currency-neutral basis and adjusted diluted earnings per share. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results, and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

We present adjusted diluted earnings per share for the second quarter and the first six months of fiscal year 2026, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction costs, separation-related costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, certain pension settlement costs, and the impact of the extinguishment of debt.

We also present revenue growth rates for the second quarter and the first six months of fiscal year 2026 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior period. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods.

New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD.

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

***

This press release and accompanying audio webcast on May 7, 2026 contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, statements relating to future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including any impact related to the imposition of (and changing policies around) new and existing tariffs enacted by the U.S. government (and related countermeasures by non-U.S. governments), or our ability to mitigate the impact of such tariffs, including developments regarding refunds of certain tariffs; import or export licensing requirements and other governmental restrictions; reductions in U.S. government funding for healthcare, disruptions in global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products; inflationary pressures, currency and interest rate fluctuations, global oil prices and increased borrowing costs; conditions in international markets, including geopolitical developments such as the continuation and/or escalation of evolving situations in Iran and the Middle East region (which could result in continued disruption of transportation lanes and global energy supplies, as well as increases in global oil prices and adversely affect our supply chain costs, ability to source raw materials and components and our ability to deliver product to customers), Ukraine and Asia; competitive factors, including changing customer and patient preferences and requirements, such as decreased demand for our products as a result of changes to U.S. federal and state policies (such as for pharmaceutical products and vaccines, and increased demand for products utilizing emerging technologies (such as artificial intelligence ("AI")), as well as new products or novel medical therapies introduced by competitors; changes in research and development efforts, investment or suspension by pharmaceuticals companies with regard to vaccine development; changes in reimbursement practices and coverage policies and third-party payer cost containment measures and health insurance coverage levels and costs; decreases or delays in purchases of our products due to reduced research and development spending; product efficacy or safety concerns and related regulatory actions, changes to the labeled indications or permitted uses of our products, non-compliance with applicable regulatory requirements regarding our products, including marketing authorization, registration, quality system and manufacturing requirements (including as a result of product modifications), or other factors that could result in product recalls, field actions, lost revenue, restrictions on our ability to continue selling existing products or commercialize new products (including limitations on future product clearances or approvals and the imposition of civil penalties); increased exposure to product liability or other claims and damage to our reputation (including products we acquire through acquisitions); changes to legislation or regulations that may impact U.S. or foreign healthcare systems, changes in medical or clinical practices or in customer and patient preferences, efforts to improve compliance of healthcare practitioners, potential cuts or freezes in healthcare spending and/or governmental or private measures to contain healthcare costs, such as China's volume-based procurement tender process or changes in pricing and reimbursement policies, which could result in reduced demand for our products or downward pricing pressure; policy and regulatory changes that may be implemented by the U.S. government, including the further elimination, downsizing and/or reduced funding of certain government agencies and programs, as well as further changes in the policy positions of such agencies (including those related to pharmaceutical products and vaccines); other new or changing laws and regulations impacting our business, including changes in tax laws, new and changing environmental laws and regulations (such as those related to sustainability, climate change or materials of concern) and new and changing cybersecurity, AI or privacy laws; other changes in laws impacting international trade or anti-corruption and bribery, or changes in reporting requirements or enforcement practices with respect to such laws; the adverse impact on our business or products of past, current or future information and technology system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, and any investigations, legal proceedings, liability, expense or reputational damage arising in connection with any such events; any adverse impact related to the development, deployment and use of AI in our products and business operations; labor disruptions; our suppliers' ability to provide products needed for our operations and BD's ability to maintain favorable supplier arrangements and relationships; increases in raw material, component, labor, duties, freight, energy and other production costs and their effect on, among other things, the cost of producing BD's products; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations; risks relating to our overall indebtedness; the possible impact of natural disasters and public health crises on our business and the global healthcare system, which could decrease demand for our products, disrupt our operations or the operations of our customers and companies within our supply chain, or increase transportation costs; interruptions in our manufacturing or sterilization processes or those of our third-party providers, including any restrictions placed on the use of ethylene oxide for sterilization; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the overall timing of the replacement or remediation of the BD Alaris™ Infusion System and return to market in the U.S., which may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA; our ability to achieve our projected level or mix of product sales; our ability to successfully integrate any businesses we acquire; uncertainties of litigation, investigations, regulatory actions, subpoenas, settlements, fines, penalties and/or other sanctions (as described in BD's filings with the Securities and Exchange Commission (the "SEC")); the issuance of new or revised accounting standards; risks associated with the separation of our former BD's Biosciences and Diagnostic Solutions and the combination of the business with Waters, including factors that could diminish our benefits from the transaction; our ability to execute our New BD strategy, Excellence Unleashed, as expected; and other factors discussed in BD's filings with the SEC. Tariff commentary is based on tariff policies in effect as of May 6, 2026. International trade policies, trade restrictions and tariffs (and related countermeasures and developments regarding refunds of certain tariffs) are rapidly evolving and there can be no assurance as to how the landscape may change and what the ultimate impact on our guidance and results of operations will be. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Three Months Ended March 31,

2026

2025

% Change

Revenues

$

4,714

$

4,480

5.2

Cost of products sold

2,560

2,619

(2.3)

Selling and administrative expense

1,213

1,117

8.6

Research and development expense

249

232

7.3

Integration, restructuring and transaction expense

533

93

471.5

Other operating expense, net

66

35

88.5

Total Operating Costs and Expenses

4,620

4,097

12.8

Operating Income

93

383

(75.6)

Interest expense

(149)

(150)

(0.7)

Interest income

9

5

102.6

Other income (expense), net

86

(36)

335.8

Income from Continuing Operations Before Income Taxes

39

201

(80.5)

Income tax provision

76

43

75.1

Net (Loss) Income from Continuing Operations

(37)

158

(123.1)

(Loss) Income from Discontinued Operations, Net of Tax

(274)

150

(283.0)

Net (Loss) Income

$     (311)

$      308

(201.0)

Basic Earnings Per Share

(Loss) Income from Continuing Operations

$    (0.13)

$      0.55

(123.6)

(Loss) Income from Discontinued Operations

(0.98)

0.52

(288.5)

Basic (Loss) Earnings per Share

$

(1.11)

$

1.07

(203.7)

Diluted Earnings Per Share

(Loss) Income from Continuing Operations

$    (0.13)

$      0.55

(123.6)

(Loss) Income from Discontinued Operations

(0.98)

0.52

(288.5)

Diluted (Loss) Earnings per Share

$

(1.11)

$

1.07

(203.7)

Average Shares Outstanding (in thousands)

Basic

280,640

287,293

Diluted

280,640

287,737

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Six Months Ended March 31,

2026

2025

% Change

Revenues

$

9,200

$

8,813

4.4

Cost of products sold

4,994

5,155

(3.1)

Selling and administrative expense

2,442

2,272

7.5

Research and development expense

484

476

1.8

Integration, restructuring and transaction expense

640

182

252.2

Other operating expense, net

78

63

24.4

Total Operating Costs and Expenses

8,639

8,147

6.0

Operating Income

562

665

(15.6)

Interest expense

(302)

(305)

(1.0)

Interest income

13

27

(52.5)

Other income (expense), net

78

(50)

257.1

Income from Continuing Operations Before Income Taxes

350

337

3.9

Income tax provision

76

33

132.6

Net Income from Continuing Operations

274

304

(10.0)

(Loss) Income from Discontinued Operations, Net of Tax

(202)

306

(166.1)

Net Income

$         72

$       611

(88.3)

Basic Earnings Per Share

Income from Continuing Operations

$      0.97

$      1.06

(8.5)

(Loss) Income from Discontinued Operations

(0.72)

1.06

(167.9)

Basic Earnings per Share

$

0.25

$

2.12

(88.2)

Diluted Earnings Per Share

Income from Continuing Operations

$      0.96

$      1.05

(8.6)

(Loss) Income from Discontinued Operations

(0.71)

1.06

(167.0)

Diluted Earnings per Share

$

0.25

$

2.11

(88.2)

Average Shares Outstanding (in thousands)

Basic

283,138

288,411

Diluted

284,634

289,193

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited; Amounts in millions)

March 31, 2026

September 30, 2025

Assets

Cash and equivalents

$

813

$

567

Restricted cash

202

210

Short-term investments

3

8

Trade receivables, net

2,205

2,396

Inventories

3,357

3,149

Prepaid expenses and other

1,432

1,379

Current assets of discontinued operations

—

1,545

Total Current Assets

8,012

9,255

Property, plant and equipment, net

6,082

6,383

Goodwill and other intangibles, net

34,303

35,190

Other assets

2,434

2,383

Noncurrent assets of discontinued operations

—

2,114

Total Assets

$

50,832

$

55,325

Liabilities and Shareholders' Equity

Current debt obligations

$

2,573

$

1,559

Other current liabilities

5,934

6,106

Current liabilities of discontinued operations

—

648

Long-term debt

14,706

17,620

Long-term employee benefit obligations

1,026

1,027

Deferred income taxes and other liabilities

2,460

2,632

Noncurrent liabilities of discontinued operations

—

342

Shareholders' equity

24,133

25,390

Total Liabilities and Shareholders' Equity

$

50,832

$

55,325

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; Amounts in millions)

Six Months Ended March 31,

2026

2025

Operating Activities

Net income

$

72

$

611

Less: (Loss) income from discontinued operations, net of tax

(202)

306

Income from continuing operations, net of tax

274

304

Depreciation and amortization

1,134

1,131

Change in operating assets and liabilities and other, net

(80)

(947)

Net Cash Provided by Continuing Operating Activities

1,328

489

Investing Activities

Capital expenditures

(233)

(219)

Maturities and sales of investments

23

413

Acquisitions, net of cash acquired and adjustments

—

13

Other, net

(111)

(136)

Net Cash (Used for) Provided by Continuing Investing Activities

(322)

71

Financing Activities

Change in short-term debt

328

340

Distribution from spin-off entity, net

3,857

—

Payments of debt

(2,000)

(875)

Repurchases of common stock

(2,250)

(750)

Dividends paid

(589)

(600)

Other, net

(63)

(81)

Net Cash Used for Continuing Financing Activities

(716)

(1,966)

Discontinued Operations

Net cash (used for) provided by operating activities

(73)

368

Net cash used for investing activities

(53)

(59)

Net cash provided by (used for) financing activities

71

(3)

      Net Cash (Used for) Provided by Discontinued Operations

(55)

306

Effect of exchange rate changes on cash and equivalents and restricted cash

3

(11)

Net increase (decrease) in cash and equivalents and restricted cash

238

(1,111)

Opening Cash and Equivalents and Restricted Cash

777

1,792

Closing Cash and Equivalents and Restricted Cash

$

1,015

$

681

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended March 31,

(Unaudited; Amounts in millions)

United States

International

Total

% Change

% Change

2026

2025

% Change

2026

2025

FX Impact

Reported

FXN

2026

2025

FX Impact

Reported

FXN

Medical Essentials(1)

Medication Delivery Solutions

$

712

$

687

3.7

$

451

$

430

$

31

4.9

(2.2)

$

1,163

$

1,117

$

31

4.1

1.4

Specimen Management

253

242

4.5

231

213

17

8.1

0.3

484

456

17

6.2

2.5

Total

$

965

$

929

3.9

$

682

$

643

$

47

6.0

(1.4)

$

1,647

$

1,573

$

47

4.7

1.7

Connected Care(1)

Medication Management Solutions

$

660

$

662

(0.2)

$

168

$

149

$

14

12.7

3.3

$

829

$

811

$

14

2.2

0.4

Advanced Patient Monitoring

180

155

15.9

112

102

4

10.0

6.2

292

257

4

13.6

12.0

Total

$

840

$

817

2.9

$

280

$

251

$

18

11.6

4.5

$

1,120

$

1,068

$

18

4.9

3.2

BioPharma Systems(1)(2)

$

178

$

149

19.4

$

411

$

426

$

25

(3.4)

(9.2)

$

590

$

575

$

25

2.5

(1.8)

Interventional(1)

Peripheral Intervention

$

279

$

269

3.9

$

236

$

212

$

15

11.1

4.1

$

515

$

481

$

15

7.1

4.0

Urology and Critical Care

351

323

8.6

79

77

4

3.0

(2.3)

430

400

4

7.5

6.5

Surgery

303

289

4.9

109

94

7

14.9

7.3

411

383

7

7.4

5.5

Total

$

933

$

880

6.0

$

423

$

384

$

26

10.4

3.6

$

1,357

$

1,264

$

26

7.3

5.3

Total Revenues from Continuing Operations

$

2,917

$

2,776

5.1

$

1,797

$

1,704

$

116

5.5

(1.4)

$

4,714

$

4,480

$

116

5.2

2.6

(1)

Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

(2)

The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Six Months Ended March 31,

(Unaudited; Amounts in millions)

United States

International

Total

% Change

% Change

2026

2025

% Change

2026

2025

FX Impact

Reported

FXN

2026

2025

FX Impact

Reported

FXN

Medical Essentials(1)

Medication Delivery Solutions

$

1,405

$

1,381

1.7

$

886

$

860

$

43

3.0

(1.9)

$

2,291

$

2,241

$

43

2.2

0.3

Specimen Management

498

481

3.7

453

437

24

3.8

(1.7)

951

917

24

3.7

1.1

Total

$

1,903

$

1,861

2.2

$

1,340

$

1,297

$

67

3.3

(1.9)

$

3,242

$

3,158

$

67

2.7

0.6

Connected Care(1)

Medication Management Solutions

$

1,339

$

1,321

1.4

$

324

$

291

$

20

11.3

4.4

$

1,663

$

1,612

$

20

3.1

1.9

Advanced Patient Monitoring

358

314

14.1

231

215

6

7.5

4.9

589

528

6

11.4

10.4

Total

$

1,697

$

1,635

3.8

$

555

$

506

$

26

9.7

4.6

$

2,252

$

2,141

$

26

5.2

4.0

BioPharma Systems(1)(2)

$

329

$

253

29.9

$

690

$

740

$

32

(6.7)

(11.0)

$

1,019

$

993

$

32

2.6

(0.6)

Interventional(1)

Peripheral Intervention

$

545

$

522

4.5

$

456

$

432

$

21

5.3

0.6

$

1,000

$

954

$

21

4.9

2.7

Urology and Critical Care

690

629

9.8

167

160

5

4.3

1.0

857

789

5

8.6

8.0

Surgery

613

591

3.6

217

187

10

16.2

10.7

829

778

10

6.6

5.3

Total

$

1,847

$

1,742

6.1

$

839

$

779

$

36

7.7

3.1

$

2,687

$

2,521

$

36

6.6

5.2

Total Revenues from Continuing Operations

$

5,776

$

5,490

5.2

$

3,424

$

3,322

$

161

3.1

(1.8)

$

9,200

$

8,813

$

160

4.4

2.6

(1)

Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the Company's product and service offerings. Subsequent to the spin-off of the company's former Biosciences and Diagnostic Solutions business (which was previously the Life Sciences segment) and the combination of the business with Waters on February 9, 2026, the Life Sciences segment was eliminated, leaving the Company with four distinct, separately-managed segments. Prior period amounts have been recast to reflect the reorganization on a continuing operations basis.

(2)

The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)

Three Months Ended March 31,

2026

2025

Change

Translational FX

FXN
Change

Change %

FXN
Change %

Reported Diluted (Loss) Earnings per Share from Continuing Operations

$

(0.13)

$

0.55

$

(0.68)

$

0.04

$

(0.72)

(123.6)

%

(130.9)

%

Purchase accounting adjustments ($368 million and $543 million pre-tax, respectively) (1)

1.31

1.89

0.01

Integration costs ($46 million and $26 million pre-tax, respectively) (2)

0.16

0.09

—

Restructuring costs ($487 million and $66 million pre-tax, respectively) (2)

1.73

0.23

0.02

Separation-related items ($40 million pre-tax) (3)

0.14

—

—

Product, litigation, and other items ($132 million and $139 million pre-tax, respectively) (4)

0.47

0.48

—

Impacts of debt extinguishment (($122) million pre-tax)

(0.43)

—

—

Dilutive impact (5)

(0.01)

—

—

Tax impact of specified items and other tax related (($97) million and ($129) million, respectively)

(0.35)

(0.45)

—

Adjusted Diluted Earnings per Share from Continuing Operations

$

2.90

$

2.79

$

0.11

$

0.08

$

0.03

3.9

%

1.1

%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities. Restructuring costs for the three months ended March 31, 2026 reflect non-cash asset impairment charges of $450 million across all reportable segments based upon the Company's commitment to exit certain operational activities and projects which no longer align with and facilitate its current operational strategy, Excellence Unleashed. These exit actions are aimed at simplifying the Company's operations and aligning resources behind its most value-creating platforms. The impairment charges are primarily reflected as decreases of $238 million within Property, plant and equipment, net, and $134 million within Goodwill and other intangibles, net, on the Company's March 31, 2026 condensed consolidated balance sheet.

(3)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(4)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the three months ended March 31, 2026 reflects charges of $42 million recorded to Cost of products sold to adjust the estimate of future product remediation costs, charges of $52 million recorded to Other operating expense, net, related to various legal matters, and a charge of $25 million to Other expense, net related to pension settlement costs. The amount for the three months ended March 31, 2025 reflects a charge of $76 million recorded to Cost of products sold to adjust the estimate of future product remediation costs and charges of $32 million recorded to Other operating expense, net, related to various legal matters.

(5)

The amount in 2026 represents the exclusion of share equivalents associated with share-based plans from the reported diluted shares outstanding calculation because such equivalents would have been antidilutive due to the net loss incurred during the period. The adjusted diluted average shares outstanding (in thousands) were 281,674.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)

Six Months Ended March 31,

2026

2025

Change

Translational FX

FXN
Change

Change %

FXN
Change %

Reported Diluted Earnings per Share from Continuing Operations

$

0.96

$

1.05

$

(0.09)

$

0.04

$

(0.13)

(8.6)

%

(12.4)

%

Purchase accounting adjustments ($751 million and $1.105 billion pre-tax, respectively) (1)

2.64

3.82

0.01

Integration costs ($82 million and $50 million pre-tax, respectively) (2)

0.29

0.17

—

Restructuring costs ($557 million and $128 million pre-tax, respectively) (2)

1.96

0.44

0.03

Transaction costs ($4 million pre-tax) (3)

—

0.01

—

Separation-related items ($41 million pre-tax) (4)

0.14

—

—

Product, litigation, and other items ($140 million and $211 million pre-tax, respectively) (5)

0.49

0.73

—

Impacts of debt extinguishment (($122) million pre-tax)

(0.43)

—

—

Tax impact of specified items and other tax related (($192) million and ($191) million, respectively)

(0.67)

(0.66)

—

Adjusted Diluted Earnings per Share from Continuing Operations

$

5.38

$

5.57

$

(0.19)

$

0.08

$

(0.27)

(3.4)

%

(4.8)

%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities. Restructuring costs for the six months ended March 31, 2026 reflect non-cash asset impairment charges of $450 million across all reportable segments based upon the Company's commitment to exit certain operational activities and projects which no longer align with and facilitate its current operational strategy, Excellence Unleashed. These exit actions are aimed at simplifying the Company's operations and aligning resources behind its most value-creating platforms. The impairment charges are primarily reflected as decreases of $238 million within Property, plant and equipment, net, and $134 million within Goodwill and other intangibles, net, on the Company's March 31, 2026 condensed consolidated balance sheet.

(3)

Represents transaction costs recorded to Integration, restructuring and transaction expense incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount for the six months ended March 31, 2026 reflects charges of $42 million recorded to Cost of products sold to adjust the estimate of future product remediation costs, charges of $63 million recorded to Other operating expense, net, related to various legal matters, and a charge of $25 million to Other expense, net, related to pension settlement costs. The amount for the six months ended March 31, 2025 reflects charges of $98 million to Cost of products sold to adjust the estimate of future product remediation costs and charges of $60 million to Other operating expense, net, related to various legal matters.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2026 GUIDANCE RECONCILIATION

Full Year FY2025

Full Year FY2026 Guidance

($ in millions)

% Change

BDX Reported Revenues from Continuing Operations

$

18,544

FY2026 Reported Revenue Growth

Low single-digit plus

Illustrative Foreign Currency (FX) Impact

~+120 basis points

FY2026 Revenue Growth (FXN)

Low single-digit

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2026 GUIDANCE RECONCILIATION CONTINUED

Full Year FY 2026 Guidance

Full Year FY2025

Total Company

Reported Diluted Earnings per Share from Continuing Operations

$

3.81

Purchase accounting adjustments ($1.865 billion pre-tax) (1)

6.46

Integration costs ($127 million pre-tax) (2)

0.44

Restructuring costs ($270 million pre-tax) (2)

0.93

Transaction costs ($6 million pre-tax) (3)

0.02

Separation-related items ($3 million pre-tax) (4)

0.01

Product, litigation, and other items ($506 million pre-tax) (5)

1.75

Tax impact of specified items and other tax related (($443) million)

(1.54)

Adjusted Diluted Earnings per Share from Continuing Operations

$

11.90

$12.52 to $12.72

Reported % Change

+5.2% to +6.9%

(1)

Includes amortization and other adjustments related to the purchase accounting for acquisitions.

(2)

Represents costs associated with integration and restructuring activities.

(3)

Represents transaction costs incurred in connection with the Advanced Patient Monitoring acquisition.

(4)

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters.

(5)

Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 reflects charges of $98 million to Cost of products sold to adjust the estimate of future product remediation costs, charges of $297 million to Other operating expense, net, related to product liability and certain other legal matters, and charges of $38 million to Other expense, net, related to pension settlement costs.

SOURCE BD (Becton, Dickinson and Company)

SummaryCompaniesStrong demand for drug delivery devices boosts company's performanceCEO Tom Polen expects injectables to remain key despite oral GLP-1 competitionCompany plans pricing actions to offset high ​oil and resin costs, appoints Vitor Roque as CFOMay 7 (Reuters) - Becton Dickinson (BDX.N), opens new tab raised annual profit forecast and beat estimates for second-quarter results on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, ​sending its shares up more than 5%.

Strong demand for injectable diabetes and obesity ​drugs of GLP-1 class has buoyed the performance of device makers ⁠such as Becton Dickinson, which makes injection pens used to administer these therapies, ​though analysts warn oral weight-loss pills could weigh.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

GLP-1 therapies remain a "strong growth driver," CEO ​Tom Polen said on a call with analysts. "Oral GLP-1 is expected to be incremental and complementary," while injectables will "continue to remain a backbone of the category for the foreseeable future," Polen said.

The ​company, which makes and distributes medical and surgical products such as needles, syringes ​and disposal units, expects its 2026 adjusted profit per share to be between $12.52 and $12.72. That compares ‌with ⁠its previous forecast of $12.35 to $12.65 per share.

Polen also said the company expects to mitigate cost pressures this year from higher oil and resin prices linked to the Middle East conflict through measures including pricing actions.

Resins and molded plastics, used to make syringes ​and catheters, account for ​about 5% of ⁠cost of goods sold, he said.

The company expects oil prices to remain high into next year and plans to offset the ​impact through diversified resin sourcing and further pricing actions.

It posted ​an adjusted ⁠profit of $2.90 per share for the quarter ended March 31, topping analysts' estimate of $2.77, according to data compiled by LSEG.

Separately, the company appointed Vitor Roque as its chief financial ⁠officer. ​Roque, a Becton Dickinson veteran for more than ​25 years, was serving as its interim CFO since December and oversaw key events including completing the separation of ​its biosciences and diagnostics business.

Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar

Our Standards: The Thomson Reuters Trust Principles., opens new tab

For the quarter ended March 2026, Becton Dickinson (BDX - Free Report) reported revenue of $4.71 billion, down 10.6% over the same period last year. EPS came in at $2.90, compared to $3.35 in the year-ago quarter.

The reported revenue represents a surprise of +1.04% over the Zacks Consensus Estimate of $4.67 billion. With the consensus EPS estimate being $2.77, the EPS surprise was +4.82%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Medical Essentials- International: $682 million versus $679.24 million estimated by two analysts on average.Revenues- Connected Care- United States: $840 million versus $819.64 million estimated by two analysts on average.Revenues- Connected Care- International: $280 million versus $268.2 million estimated by two analysts on average.Revenues- Connected Care- Medication Management Solutions- International: $168 million versus $156.64 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.Revenues- Interventional- Surgery: $411 million compared to the $410.67 million average estimate based on three analysts. The reported number represents a change of +7.3% year over year.Revenues- Interventional- Peripheral Intervention: $515 million versus the three-analyst average estimate of $507.53 million. The reported number represents a year-over-year change of +7.1%.Revenues- Interventional- Urology and Critical Care: $430 million versus $438.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change.Revenues- Connected Care- Medication Management Solutions: $829 million versus $819.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.2% change.Revenues- Connected Care: $1.12 billion compared to the $1.1 billion average estimate based on three analysts.Revenues- Medical Essentials: $1.65 billion versus the three-analyst average estimate of $1.62 billion. The reported number represents a year-over-year change of -40.3%.Revenues- BioPharma Systems: $590 million versus $580.75 million estimated by three analysts on average.Revenues- Medical Essentials- Medication Delivery Solutions: $1.16 billion versus $1.15 billion estimated by three analysts on average.View all Key Company Metrics for Becton Dickinson here>>>

Shares of Becton Dickinson have returned -7.9% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways BDX delivered adjusted EPS of $2.90 on revenues of $4.71 billion, beating consensus estimates.BD's all segments grew on a reported basis, led by Interventional and Medical Essentials revenue gains.BDX expanded gross and operating margins as gross profit and adjusted operating profit rose year over year. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, delivered adjusted earnings per share (EPS) of $2.90 in the second quarter of fiscal 2026, up 3.9% year over year. The figure topped the Zacks Consensus Estimate by 4.8%.

The adjustments include expenses related to purchase accounting adjustments and restructuring costs, among others.

GAAP loss per share for the quarter was 13 cents against the year-ago quarter’s EPS of 55 cents.

BDX’s Revenues in DetailBD registered revenues of $4.71 billion in the fiscal second quarter, up 5.2% year over year on a reported basis. The figure surpassed the Zacks Consensus Estimate by 1%.

At constant exchange rate (CER), revenues climbed 2.6% year over year.

Robust performances by all the segments on a reported basis drove the top-line improvement.

Shares of this company gained nearly 2.5% in today’s pre-market trading.

BD’s Segment DetailsEffective Oct. 1, 2025, BD had reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of its product and service offerings. However, subsequent to the spin-off of BDX's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the company with four distinct, separately-managed segments.

In the quarter under review, the Medical Essentials segment reported revenues of $1.65 billion, up 4.7% and 1.7% from the year-ago quarter on a reported basis and at CER, respectively.

Revenues in the Connected Care segment totaled $1.12 billion, up 4.9% year over year on a reported basis and 3.2% at CER.

BioPharma Systems segment generated revenues of $590 million, up 2.5% from the year-ago quarter on a reported basis, but down 1.8% at CER.

BD Interventional segment generated revenues of $1.36 billion, up 7.3% from the year-ago quarter on a reported basis and 5.3% at CER.

BDX’s Geographic ResultsIn the second quarter of fiscal 2026, revenues in the United States improved 5.1% year over year to $2.92 billion.

International revenues grossed $1.79 billion, up 5.5% from the year-ago quarter on a reported basis, but down 1.4% at CER.

BD’s Margin AnalysisIn the quarter under review, BD’s gross profit increased 15.7% year over year to $2.15 billion. The gross margin expanded 415 basis points (bps) to 45.7%.

Selling and administrative expenses increased 8.6% year over year to $1.21 billion. Research and development expenses increased 7.3% year over year to $249 million. Adjusted operating expenses of $1.46 billion rose 8.4% year over year.

Adjusted operating profit totaled $692 million, reflecting a 35.2% increase from the year-ago quarter. The adjusted operating margin in the fiscal second quarter expanded 325 bps to 14.7%.

BDX’s Financial PositionBD exited second-quarter fiscal 2026 with cash and cash equivalents and short-term investments of $816 million compared with $751 million at the fiscal first-quarter end. Total debt (including current debt obligations) at the end of the fiscal second quarter was $17.28 billion compared with $19.54 billion at the fiscal first-quarter end.

Cumulative net cash provided by continuing operating activities at the end of second-quarter fiscal 2026 was $1.33 billion compared with $489 million a year ago.

Meanwhile, BD has a consistent dividend-paying history, with its five-year annualized dividend growth being 5.47%.

BD’s Fiscal 2026 GuidanceBD has revised guidance for fiscal 2026 for New BD.

BD continues to project its full fiscal year revenues to grow above low single-digit on a reported basis, while it continues to expect them to grow at low single-digit at CER.

For the full fiscal year, adjusted EPS is now anticipated to be in the range of $12.52-$12.72, up from the prior outlook of $12.35-$12.65. The Zacks Consensus Estimate is pegged at $12.53.

Our Take on BDBD exited the second quarter of fiscal 2026 with better-than-expected results and solid top-line results. Robust performances by all segments and both geographic regions on a reported basis were encouraging. The expansion of both margins bodes well.

Apart from these, there were a few other developments during the recent period. BDX announced the commercial launch of the BD CentroVena One Insertion System (Medical Essentials segment), the BD Pyxis Pro Dispensing Solution, the BD Incada Connected Care Platform in Europe and the HemoSphere Stream Module (all within the Connected Care segment). The company also progressed on the regulatory front, where it received CE Marking for the Revello Vascular Covered Stent and the Liverty TIPS Stent Graft and FDA 510(k) clearance for Surgiphor 1000mL (all within the Interventional segment). BD also announced a few collaborations during the reported quarter. These raise our optimism about the stock.

However, lower revenues from the BioPharma Systems segment and the international revenues at CER were disappointing.

BD’s Zacks Rank and Key PicksBDX currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space that have announced quarterly results are BrightSpring Health Services, Inc. (BTSG - Free Report) , DaVita Inc. (DVA - Free Report) and Labcorp Holdings Inc. (LH - Free Report) .

BrightSpring, sporting a Zacks Rank of 1 (Strong Buy), reported first-quarter 2026 adjusted EPS of 39 cents, beating the Zacks Consensus Estimate by 35.4%. Revenues of $3.61 billion outpaced the consensus mark by 8.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring has a long-term estimated growth rate of 44.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

DaVita reported first-quarter 2026 adjusted EPS of $2.87, beating the Zacks Consensus Estimate by 19.1%. Revenues of $3.42 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).

DaVita has a long-term estimated growth rate of 20.2%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.4%.

Labcorp reported first-quarter 2026 adjusted EPS of $4.25, beating the Zacks Consensus Estimate by 3.9%. Revenues of $3.54 billion surpassed the Zacks Consensus Estimate by 1%. It currently carries a Zacks Rank #2.

Labcorp has a long-term estimated growth rate of 7.9%. LH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.

MarketBeat Instant News Alerts

2 hours ago

Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of StockMarketBeat

MarketAxess Holdings Inc. (NASDAQ:MKTX - Get Free Report) General Counsel Scott Pintoff sold 100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $116.03, for a total transaction of $11,603.00. Following the transaction, the general counsel owned 11,786 shares in the company, valued at approximately $1,367,529.58. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:MKTX

Read Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of Stock

Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 327

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

Peter Menziuso, Executive Vice President and President, BD Interventional Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a $5 billion global business with responsibility for commercial operations, R&D, supply chain, quality, finance and medical affairs.

Throughout his career, Menziuso has been recognized for strengthening market leadership, building high‑performing teams and translating strategy into sustained performance through commercial rigor and operational excellence. His global leadership experience, coupled with his customer obsession and ability to lead at scale position him well to accelerate execution and deliver continued growth for BD Interventional.

"BD Interventional has a strong track record of performance, and Peter is the right leader to build on that momentum and continue delivering results," said Tom Polen, chairman, CEO and president of BD. "Peter brings a strong combination of strategic leadership and operational discipline. He is grounded in delivering for customers and patients, building strong teams and driving consistent performance, positioning the business for sustained growth and continued strength across the portfolio."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X  @BDandCo or Instagram @becton_dickinson.

SOURCE BD (Becton, Dickinson and Company)

Key Takeaways BD unveiled the Elyra TFL System, expanding its U.S. kidney stone management offerings for urology teams.Elyra TFL tech aids stone dusting, cuts migration and stays quiet with a compact air-cooled design.First Elyra Plus cases got positive feedback, with presets and a wireless footswitch option. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the launch of the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform within its kidney stone care portfolio. The system is designed to improve efficiency, versatility and procedural workflow across urologic stone management and soft tissue procedures.

Management stated that Elyra reflects BD’s commitment to rapid innovation by delivering technology that enables clinicians to provide efficient, high-quality patient care. The combination of advanced TFL technology and a clinician-centric design, Elyra streamlines kidney stone treatment while offering greater adaptability across a wide range of procedures.

Likely Trend of BDX Stock Following the NewsFollowing the announcement, BDX shares lost 0.5% at yesterday’s closing. In the year-to-date period, shares of the company have declined 24.7% compared with the industry’s 9.4% fall. However, the S&P 500 has risen 9.1% in the same timeframe.

The introduction of the Elyra TFL System may strengthen investor confidence in BD’s urology and medical technology portfolio. Expanding its end-to-end kidney stone management offerings could support broader adoption among healthcare providers and enhance BD’s competitive positioning in the growing urologic care market. Continued innovation and clinician-focused product development may contribute to long-term growth opportunities for the company.

BDX currently has a market capitalization of $40.49 billion.

Image Source: Zacks Investment Research

More on the Elyra TFL SystemThe Elyra TFL System utilizes advanced Thulium Fiber Laser technology to support efficient stone dusting and reduce stone migration. The system’s air-cooled design enables quieter operation and a smaller footprint. BD is offering the platform in two configurations — Elyra and Elyra Plus — allowing flexibility to meet varying operational requirements.

The Elyra TFL System features an intuitive user interface, quick startup, customizable presets and an optional wireless footswitch to simplify workflows in stone lithotripsy and soft tissue procedures. The platform also enables faster advancements for future technology generations to address evolving clinician and patient needs.

BD recently carried out its first clinical procedures using the Elyra Plus TFL System at a leading medical center. Urologists and laser technicians reported positive experiences with the system’s usability and integrated safety features.

With Elyra, BD continues to strengthen its urologic stone management portfolio, offering solutions across access, dilation, visualization, fragmentation, removal and drainage. The Elyra and Elyra Plus TFL Systems are currently available in the United States.

Industry Prospects Favoring the MarketGoing by the data provided by Fortune Business Insights, the urology lasers market is valued at $1.37 billion in 2026 and is expected to witness a CAGR of 7.2% through 2033.

Factors like the rising prevalence of urological disorders, growing demand for minimally invasive procedures and strong momentum for thulium fiber laser adoption are driving the market’s growth.

Other NewsRecently, BD exited the second quarter of fiscal 2026 with better-than-expected results and solid top-line results. Robust performances by all segments and both geographic regions on a reported basis were encouraging.

Apart from these, there were a few other developments during the recent period. BDX announced the commercial launch of the BD CentroVena One Insertion System (Medical Essentials segment), the BD Pyxis Pro Dispensing Solution, the BD Incada Connected Care Platform in Europe and the HemoSphere Stream Module (all within the Connected Care segment). The company also progressed on the regulatory front, where it received CE Marking for the Revello Vascular Covered Stent and the Liverty TIPS Stent Graft and FDA 510(k) clearance for Surgiphor 1000mL (all within the Interventional segment).

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.